Cora Capital Advisors’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Cora Capital Advisors’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-38,960	Closed	-$799K	–	117
2025 Q2	$799K	Sell	38,960 -4,396	-10%	-$88.5K	0.36%	44
2025 Q1	$888K	Sell	43,356 -1,098	-2%	-$24.5K	0.43%	41
2024 Q4	$1.01M	Sell	44,454 -2,781	-6%	-$66.8K	0.49%	35
2024 Q3	$1.16M	Sell	47,235 -180	-0.4%	-$4.39K	0.57%	33
2024 Q2	$1.1M	Buy	47,415 +2,995	+7%	+$70.1K	0.56%	35
2024 Q1	$1.07M	Buy	44,420 +2,899	+7%	+$68K	0.57%	33
2023 Q4	$955K	Buy	41,521 +4,728	+13%	+$95K	0.56%	33
2023 Q3	$749K	Buy	36,793 +4,157	+13%	+$93.3K	0.5%	39
2023 Q2	$762K	Buy	32,636 +16,302	+100%	+$391K	0.51%	37
2023 Q1	$380K	Buy	+16,334	New	+$409K	0.28%	51

Other funds holding IDNA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Cora Capital Advisors's IDNA Position: Q3 2025 in Review

Cora Capital Advisors sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q3 2025, closing a stake of 38,960 shares — an estimated $799K sold.

Cora Capital Advisors first reported a position in IDNA in Q1 2023 and held it in 10 quarters. The position peaked at $1.16M in Q3 2024. 51 funds tracked by Wall St. Rank hold IDNA as of Q3 2025.

Cora Capital Advisors reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q3 2025 after selling out during the quarter.
Cora Capital Advisors sold 38,960 iShares Genomics Immunology and Healthcare ETF shares in Q3 2025, an estimated $799K.
Cora Capital Advisors first reported a position in iShares Genomics Immunology and Healthcare ETF in Q1 2023 and held it in 10 quarters.
Cora Capital Advisors's iShares Genomics Immunology and Healthcare ETF position peaked at $1.16M in Q3 2024.
51 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q3 2025.

Based on Cora Capital Advisors's 13F filing for Q3 2025, filed 7 Nov 2025.